trial · primary record
Venetoclax
Diffuse Large B-cell Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 78 |
| Primary completion | 2024-09-01 |
| Primary endpoint | Maximum tolerated dose (escalation) |
| Registry ID | NCT03955783 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:24.317Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03955783
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- VENETOCLAX · approval
- Venetoclax · compound